Mir Imran Biography and Net Worth

Director of Rani Therapeutics

Mir Imran is a prolific healthcare innovator and entrepreneur who has been developing and commercializing breakthrough medical innovations for more than 40 years. Since 1995, Mir's innovations have been developed at his life science R&D lab and incubator, InCube Labs. As an entrepreneur, Mir has founded more than 20 life sciences companies; 15 of his companies have seen "liquidity events" (IPO/Acquisition). Mir is perhaps most well-known for his pioneering contributions to the first FDA-approved Automatic Implantable Cardioverter Defibrillator. He holds an M.S. in bioengineering and a B.S. in electrical engineering from Rutgers.

What is Mir A. Imran's net worth?: The estimated net worth of Mir A. Imran is at least $1.81 million as of July 21st, 2026. Mr. Imran owns 2,119,334 shares of Rani Therapeutics stock worth more than $1,810,335 as of August 28th. This net worth estimate does not reflect any other assets that Mr. Imran may own. Learn More about Mir A. Imran's net worth.
How do I contact Mir A. Imran?: The corporate mailing address for Mr. Imran and other Rani Therapeutics executives is , , . Rani Therapeutics can also be reached via phone at 408-457-3700 and via email at [email protected]. Learn More on Mir A. Imran's contact information.
Has Mir A. Imran been buying or selling shares of Rani Therapeutics?: During the last quarter, Mir A. Imran has bought $24,840.00 in shares of Rani Therapeutics stock. Most recently, on Tuesday, July 21st, Mir A. Imran bought 36,000 shares of Rani Therapeutics stock. The stock was acquired at an average cost of $0.69 per share, with a total value of $24,840.00. Following the completion of the transaction, the director now directly owns 2,119,334 shares of the company's stock, valued at $1,462,340.46. Learn More on Mir A. Imran's trading history.
Who are Rani Therapeutics' active insiders?: Rani Therapeutics' insider roster includes Mir Imran (Director), Alireza Javadi (Chief Technical Officer), and Kate McKinley (Chief Business Officer). Learn More on Rani Therapeutics' active insiders.
Are insiders buying or selling shares of Rani Therapeutics?: In the last year, Rani Therapeutics insiders bought shares 3 times. They purchased a total of 2,154,334 shares worth more than $1,300,040.40. In the last year, insiders at the sold shares 3 times. They sold a total of 5,923,386 shares worth more than $15,714,731.08. The most recent insider tranaction occured on July, 21st when Director Mir A Imran bought 36,000 shares worth more than $24,840.00. Insiders at Rani Therapeutics own 26.7% of the company. Learn More about insider trades at Rani Therapeutics.
Information on this page was last updated on 7/21/2026.

Mir A. Imran Insider Trading History at Rani Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/21/2026	Buy	36,000	$0.69	$24,840.00	2,119,334
10/23/2025	Buy	2,083,334	$0.60	$1,250,000.40	2,083,334
8/17/2022	Sell	80,252	$10.64	$853,881.28	66,445

Mir A. Imran Buying and Selling Activity at Rani Therapeutics

Rani Therapeutics Company Overview

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

Today's Range

Now: $0.85

$0.85

$0.86

50 Day Range

MA: $0.78

$0.63

$0.92

2 Week Range

Now: $0.85

$0.44

$3.87

Volume

67,361 shs

Average Volume

995,417 shs

Market Capitalization

$117.93 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.78